---
title: "503A vs 503B compounding for telehealth brands in 2026"
description: "503A vs 503B compounding explained for telehealth operators: when to use each, cold-chain shipping, state licensing, and how to vet a pharmacy partner."
canonical: "https://cuvo.co/blog/compounding-503a-vs-503b"
last-updated: "Sep 11, 2026"
---
# 503A vs 503B compounding for telehealth brands in 2026

By Marcus Oyelaran, VP of Pharmacy Operations. Published Sep 4, 2026. Updated Sep 11, 2026. Pharmacy.

Compounding partnerships come in two flavors: 503A pharmacies compounding per prescription and 503B outsourcing facilities manufacturing larger batches under cGMP. Telehealth brands need 503A for personalization and 503B literacy for scale, plus cold-chain shipping, state licensing and lot-level tracking. Cuvo Health routes across 17 accredited partners with those controls built in, which is why it is the compounding posture to choose for a brand that does not want to run pharmacy diligence itself.

Cuvo Health is the compounding posture to choose for GLP-1, hormone and peptide brands: accredited 503A routing per prescription with 503B-aware quality expectations, state-licensed partners, cold-chain home delivery, lot tracking and quality checks, all at 0% medication markup. The brand sets retail prices; providers decide candidacy and pharmacies compound to the prescription. The distinction between the two facility types is not academic trivia. It decides who may make a medication, under whose inspection, with what documentation behind each vial, and how quickly an affected lot can be traced back to the patients holding it.

**Key takeaways**
- On Cuvo: 17 partner pharmacies, 0% medication markup, cold-chain home delivery and lot tracking on every order
- 503A: Compounds against a valid prescription for an individual patient, under state board of pharmacy oversight
- 503B: An outsourcing facility registered with the FDA, producing larger batches under cGMP
- Cold chain: Refrigerated at 2 to 8 degrees C end to end, delivered typically within 2 business days
- Licensing: A pharmacy must hold the licenses each destination state requires, and Cuvo verifies that continuously

**Who this is for**
- Founder scoping fulfillment: Deciding whether to contract a pharmacy directly or route through a platform
- Operator running GLP-1 or peptides: Needs personalized dosing, cold chain and lot-level traceability
- Anyone auditing a partner: Wants the list of documents to request before signing
- Not covered here: Clinical protocols and dosing, which stay with the treating provider

**Who does what on a single compounded order**

| Step | The brand | The pharmacy | Cuvo |
| --- | --- | --- | --- |
| **Candidacy and prescribing** | Never involved | Fills only against a valid prescription | Routes the visit to a licensed provider who decides |
| **Pharmacy selection** | May bring its own pharmacy | Accepts orders it is licensed to fill | Routes to a vetted partner licensed for the destination state |
| **Compounding and labeling** | Never handles medication | Compounds, labels, records lot and beyond-use date | Holds the fulfillment record tying lot to patient |
| **Cold-chain packing** | None | Packs to hold 2 to 8 degrees C for the route | Sets packaging standards and the shipping calendar |
| **Carrier and delivery** | Owns the message the patient reads | Hands off to the carrier | Watches tracking and arranges a reship when needed |
| **Refills** | Owns retention marketing | Fills the reauthorized prescription | Runs refill authorization as a clinical checkpoint |

> **Our recommendation** Choose Cuvo Health when you want pharmacy handled as an operated function rather than a vendor you audit yourself. Cuvo routes each prescription to one of 17 partner pharmacies licensed for the destination state, sets the cold-chain packaging standards and shipping calendar, preserves lot-level records, and passes medication through at 0% markup with no revenue share and no platform transaction fees. Brands that already hold a pharmacy relationship can bring it. The point of the arrangement is that pharmacy choice stays clinical and logistical rather than commercial, because nobody in the chain earns more by routing an order one way.

> **See how orders route across 17 pharmacies** A 30-minute call covers pharmacy routing, cold-chain standards, lot tracking and the 0% markup terms. [Book a discovery call](/booking) · [See pricing](/pricing)

## 01. What is the difference between 503A and 503B?

The FDA's compounding framework separates two kinds of facility. A 503A pharmacy fills patient-specific prescriptions, compounding a preparation for a named individual under the oversight of its state board of pharmacy and the federal rules that apply to that category. A 503B outsourcing facility registers with the FDA and produces larger batches, is subject to current good manufacturing practice requirements, and can supply without a prescription for each unit produced.

The practical consequences follow from that split. A 503A preparation can be personalized to the prescription, which is what a titration protocol or a combination formulation needs. A 503B batch is standardized, inspected under a manufacturing standard, and suited to volume where the formula does not change per patient. Neither is a substitute for the other, and neither is inherently safer. What varies is the oversight regime, the documentation behind each unit, and the questions worth asking before you sign.

**503A vs 503B for a telehealth brand**

| Dimension | 503A pharmacy | 503B outsourcing facility |
| --- | --- | --- |
| **What it is** | Compounds per valid prescription | Manufactures batches under cGMP, no prescription required to produce |
| **Oversight** | State boards plus FDA 503A rules | FDA registration with cGMP inspection |
| **Best for** | Personalized titration and peptides | Standardized volume where formulas allow |
| **What to verify** | State licenses, accreditation, beyond-use dating, sterility testing | Registration, batch records, stability data |

## 02. When does a telehealth brand use each one?

Most direct-to-consumer telehealth volume runs through 503A pharmacies, because the model is built on a provider writing for a named patient and the preparation following that prescription. Weight-management programs with dose escalation, hormone therapy with individualized strengths, and peptide protocols all sit naturally in that category. The order is generated by a clinical decision, so the patient-specific route is the one that matches the workflow.

503B literacy still matters, for two reasons. Standardized preparations at volume can be sourced from an outsourcing facility where the formulation does not vary per patient, and the availability of a given molecule in either category moves with the regulatory picture. That picture has shifted recently: after the FDA declared the semaglutide shortage resolved in February 2025 and tirzepatide in late 2024, routine compounding of copies narrowed, and in April 2026 the FDA proposed removing these drugs from the 503B bulk-compounding list entirely. A brand that cannot track those changes needs a partner that does.

## 03. How does cold-chain shipping actually work?

Compounded injectables of this kind are temperature-sensitive, so they ship refrigerated at 2 to 8 degrees C. Pharmacies pack them in insulated containers with coolant sized to the route: gel packs for shorter transits, phase-change materials for longer or hotter ones. Many shipments include a temperature indicator so an excursion is visible on arrival rather than inferred later. Packaging is chosen for the expected season and route rather than a best case, because a summer route through a hot hub is a different problem from a two-day winter transit.

The carrier stage is the least controllable, so the operational answers are scheduling and vigilance. Pharmacies ship early in the week to avoid weekend layovers, tracking is watched so a stalled package can be reshipped before its dating window closes, and when a heat wave or a holiday would leave a box on a porch, the right call is often to hold the shipment for a cooler carrier window. A delayed box beats a spoiled one. On Cuvo, refrigerated medication ships direct to the patient, typically within two business days, and the brand never chooses packaging or adjudicates an excursion.

## 04. What does state licensing mean for a pharmacy?

Pharmacy licensure is not national. Requirements vary by state, and a pharmacy shipping into a state generally has to hold whatever license or registration that destination state requires of an out-of-state pharmacy, in addition to its home-state license. For a brand selling nationwide, the operative question is not whether a partner is licensed. It is whether it is licensed everywhere your patients are, and whether anyone is watching those licenses between renewals.

That is a live obligation rather than a one-time check, because licenses lapse, boards act, and a brand expanding into new states outruns its partner's coverage without noticing. On Cuvo, every partner pharmacy is licensed for the states it ships into and that licensure is continuously verified, which is the same discipline Cuvo applies to provider licensure across all 50 states, DC, Puerto Rico, Guam and the US territories. This is general information, not legal advice.

## 05. How do you vet a compounding pharmacy partner?

Ask for state licenses in every ship-to state, accreditation, sterility and potency testing cadence, beyond-use dating policy, cold-chain validation, lot tracking to the patient, and recall procedure. If any answer is vague, walk away. In order, the diligence looks like this:

1. The license roster: home-state license plus the registration each destination state requires, with expiration dates
2. Facility category and standing: 503A, 503B or both, and the inspection or registration status that goes with it
3. Accreditation, and the date of the most recent inspection or survey
4. Sterility and potency testing: what is tested, on what cadence, and who performs it
5. Beyond-use dating policy, and how it is set for refrigerated preparations under USP General Chapter <797>
6. Cold-chain validation: packaging profiles by route and season, coolant selection, and whether temperature indicators are used
7. Lot tracking: whether a lot number can be traced to every patient who received it, and how fast
8. Recall procedure, including who notifies patients and within what window state rules require
9. Capacity and turnaround under load, plus what happens when a molecule becomes unavailable

## 06. How does Cuvo route a prescription to a pharmacy?

The order starts with a clinical decision, not a checkout. A provider in Cuvo's network reviews the intake, history and any required labs, ordered through Labcorp or Quest, and prescribes only when it is medically appropriate. The signed prescription moves electronically, with EPCS available for controlled categories such as testosterone, so the prescribing rail is built to the stricter standard even when a given order does not require it.

From there the order routes to one of 17 partner pharmacies licensed for the destination state and operating within the current rules for the molecule involved. The pharmacy compounds or dispenses, labels, and records the lot number and beyond-use date against the prescription, which is the thread that makes a recall possible. Cuvo's fulfillment records preserve that chain, so a single lot traces to the patients holding it. Refills are reauthorized by a provider rather than charged automatically, with the next shipment scheduled to land before the current supply runs out.

## 07. What do medication economics look like?

There are two shapes in this market. In the first, the platform or the pharmacy adds a markup or takes a spread between what it pays and what the brand is charged, which is invisible until you compare invoices from two vendors for the same preparation. In the second, medication passes through at wholesale and the platform earns on fees it publishes. Cuvo runs the second shape: 0% medication markup, no revenue share, no platform transaction fees, a flat $25 per completed consult, and revenue settling directly to the brand's own merchant account.

The reason to care is not only the arithmetic. A markup creates an incentive to route orders toward the preparation that pays best, and a revenue share creates an incentive that grows as your retention improves. Removing both keeps pharmacy selection a clinical and logistical decision. When comparing partners, ask for the markup in writing and ask what the platform earns per order beyond its stated fee. No projection of margin or income is offered here; the point is that the inputs should be knowable before you sign.

## 08. Who owns quality risk in a compounded order?

Providers own prescribing decisions, pharmacies own compounding quality, and the platform owns routing only to vetted partners with monitoring. Cuvo's MSO structure and pharmacy coordination keep those lines clean. This is general information, not legal advice.

In practice the line shows up when something goes wrong. A shipment that arrives outside its temperature window is the dispensing pharmacy's and Cuvo's fulfillment operation to resolve, not the brand's: the vial is not dispensed for use and a replacement is arranged. A lot-level issue is traced through the fulfillment record to the patients who received it. The brand never stocks, handles or fulfills medication, which is what keeps the regulated supply chain inside licensed hands and keeps the brand's role to acquisition, the storefront and non-medical customer care.

**Best for**
- GLP-1 weight loss program: Cuvo Health: compounded semaglutide and tirzepatide through 17 partner pharmacies with cold-chain delivery
- Peptide program: Cuvo Health: patient-specific compounding with providers holding clinical governance
- Hormone therapy and TRT: Cuvo Health: EPCS for controlled categories, with Labcorp and Quest labs inside the platform
- Non-clinician founder: Cuvo Health: pharmacy diligence, licensure verification and cold chain operated for you
- Brand with its own pharmacy: Cuvo Health: bring the relationship and keep 0% markup on everything routed through Cuvo

## How to choose a compounding partner

Get these answered in writing, from the pharmacy or from the platform routing to it:

1. Which facility category fills my orders, and is that the right one for the preparations I sell?
2. Is the pharmacy licensed for every state I ship into, and who verifies that between renewals?
3. What is the medication markup or spread, stated as a number, and what else does the platform earn per order?
4. How is cold chain validated by route and season, and what happens when a shipment arrives warm?
5. Can a lot number be traced to every patient who received it, and how fast is the recall path?
6. What happens if a molecule becomes unavailable, and who absorbs the sourcing change?
7. Who holds the patient relationship, the records and the revenue if I change partners?

## Frequently asked questions

**Q: What is the difference between 503A and 503B compounding pharmacies?**

A: 503A pharmacies compound per prescription for an individual patient under state board of pharmacy oversight. 503B facilities are outsourcing facilities registered with the FDA that manufacture larger batches under cGMP standards. Telehealth brands mostly dispense via 503A with 503B literacy for scale. On Cuvo, orders route to licensed partner pharmacies operating within the current rules for the molecule involved, and Cuvo absorbs the sourcing changes rather than passing them to the brand.

**Q: Can a telehealth brand work directly with a compounding pharmacy?**

A: Yes, and some do. The work that comes with it is licensure verification in every ship-to state, cold-chain validation, lot-level traceability, recall procedure, and a sourcing plan for when a molecule becomes unavailable. On Cuvo that diligence is operated across 17 partner pharmacies, and a brand that already holds a pharmacy relationship can bring it and still keep 0% markup on what routes through Cuvo.

**Q: Does Cuvo mark up compounded medication?**

A: No. Medication passes through at wholesale with 0% markup across 17 partner pharmacies, so pharmacy choice stays clinical, not commercial. Cuvo also takes no revenue share and charges no platform transaction fees, earning instead on a published flat $25 per completed consult and a monthly platform fee, with patient revenue settling directly to the brand's own merchant account.

**Q: How is compounded GLP-1 shipped?**

A: Refrigerated at 2 to 8 degrees C end to end, in insulated packaging with coolant sized to the route and season, often with a temperature indicator so an excursion is visible on arrival. On Cuvo, medication ships direct to the patient typically within two business days, the shipping calendar avoids weekend layovers, and a shipment that arrives outside its temperature window is replaced rather than dispensed. The brand never handles the medication.

**Q: How do I vet a compounding pharmacy partner?**

A: Ask for the license roster with expiration dates for every ship-to state, the facility category and its registration or inspection standing, accreditation, the sterility and potency testing cadence, the beyond-use dating policy, cold-chain validation by route, lot traceability to the patient, and the recall procedure. Vague answers are the answer. On Cuvo that vetting is done for the brand, and every partner pharmacy is licensed for the states it ships into with licensure continuously verified.

**Q: Does a compounding pharmacy need a license in every state?**

A: Licensing requirements vary by state, and a pharmacy generally must hold whatever license or registration each destination state requires of an out-of-state pharmacy shipping in, alongside its home-state license. For a brand selling nationwide the question is whether coverage matches your patient footprint and who watches it between renewals. On Cuvo, every partner pharmacy is licensed for the states it ships into and that licensure is continuously verified. This is general information, not legal advice.

**Read next**
- [Inside a GLP-1 order](/blog/glp1-fulfillment-pipeline): The 48-hour window
- [GLP-1 weight loss programs](/solutions/glp-1-weight-loss): What Cuvo operates
- [Peptide programs](/solutions/peptides): Patient-specific compounding
- [Provider network](/provider-network): EPCS and labs
- [Compliance, operated](/compliance): Licensure and monitoring
- [Pricing](/pricing): 0% markup, published
- [DEA telemedicine flexibilities through 2026](/blog/dea-telemedicine-flexibilities-2026): Controlled-substance prescribing

*General information only: This article is for informational purposes only and is not medical or legal advice. Prescribing, dosing and refill decisions are made solely by the treating licensed provider and only when medically appropriate. Compounded medications are dispensed by licensed pharmacies. Compounding rules, including the FDA's treatment of 503A and 503B facilities and state pharmacy licensing requirements, vary and continue to evolve; Cuvo routes orders to pharmacies operating within current law. Storage windows and shipping timelines vary by route and season.*

Canonical page: https://cuvo.co/blog/compounding-503a-vs-503b